BBB-Targeting Liposomes for Selective Brain Drug Delivery

The patent uses liposomes as intermediary carriers that can interact with BBB transport systems without disrupting the barrier. The liposomes are designed to be recognized by BBB transport mechanisms (such as LDL receptors or transferrin receptors), allowing them to cross the BBB through physiological pathways rather than forcing permeation that would damage the barrier.

The patent modifies the physical and chemical parameters of drug delivery by encapsulating drugs in liposomes with specific surface properties, sizes, and compositions. These parameter changes allow the delivery system to exploit BBB transport mechanisms while maintaining barrier integrity, rather than using high concentrations or harsh methods that would disrupt the BBB.

The patent separates the drug from the BBB-crossing function by using liposomes as distinct carriers. The liposome surface is modified with ligands that recognize BBB transport systems, while the therapeutic drug remains encapsulated inside. This segmentation allows the crossing function and therapeutic function to be independently optimized, maintaining drug specificity while enabling BBB penetration.

The liposome acts as an intermediary that carries the drug across the BBB without requiring the drug itself to be modified. The liposome surface contains recognition elements that interact with BBB transport systems, while the enclosed drug maintains its original therapeutic properties and specificity.